Literature DB >> 23562307

Inflammatory pre-conditioning of mesenchymal multipotent stromal cells improves their immunomodulatory potency in acute pyelonephritis in rats.

Egor Y Plotnikov1, Natalya V Pulkova, Irina B Pevzner, Ljubava D Zorova, Denis N Silachev, Maria A Morosanova, Gennady T Sukhikh, Dmitry B Zorov.   

Abstract

BACKGROUND AIMS: Acute pyelonephritis is one of the most frequent infectious diseases of the urinary tract and a leading cause of kidney failure worldwide. One strategy for modulating excessive inflammatory responses in pyelonephritis is administration of mesenchymal multipotent stromal cells (MMSCs).
METHODS: The putative protective effect of injection of MMSCs against experimental acute pyelonephritis was examined. We used in vivo experimental model of APN where bacteria are introduced in the bladder of rat. Three days after, intravenous injection of MMSCs was done. On the 7th day blood samples and kidneys were taken for further analysis.
RESULTS: We found obvious signs of oxidative stress and inflammation in the kidney in acute pyelonephritis in rats. Particularly, pro-inflammatory cytokine tumor necrosis factor-α levels, malondialdehyde, nitrite and myeloperoxidase activity were significantly increased. Histologic evaluation revealed numerous attributes of inflammation and tissue damage in the kidney. Treatment with MMSCs caused a remarkable decrease of all of these pathologic signs in renal tissue. Also, activated leukocytes induced pre-conditioning-like signaling in MMSCs. We showed alterations of expression or activity of inducible nitric oxide synthase, transforming growth factor-β, matrix metalloproteinase-2 and glycogen synthase kinase-3β, which could mediate immunomodulation and protective effects of MMSCs. This signaling could be characterized as inflammatory pre-conditioning.
CONCLUSIONS: The beneficial capacity of MMSCs to alleviate renal inflammation was more pronounced when pre-conditioned MMSCs were used. This approach could be used to prime MMSCs with different inflammatory modulators to enhance their engraftment and function in an immunoprotected fashion.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562307     DOI: 10.1016/j.jcyt.2013.02.003

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  ReNCell VM conditioned medium enhances the induction of dental pulp stem cells into dopaminergic like cells.

Authors:  Nareshwaran Gnanasegaran; Vijayendran Govindasamy; Sabri Musa; Noor Hayaty Abu Kasim
Journal:  Cytotechnology       Date:  2014-10-17       Impact factor: 2.058

Review 2.  Mesenchymal Stem Cell-Macrophage Choreography Supporting Spinal Cord Repair.

Authors:  Inés Maldonado-Lasunción; Joost Verhaagen; Martin Oudega
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

3.  Comparative Pharmacokinetics of Gallic Acid, Protocatechuic Acid, and Quercitrin in Normal and Pyelonephritis Rats after Oral Administration of a Polygonum capitatum Extract.

Authors:  Yong Huang; Zuying Zhou; Wu Yang; Zipeng Gong; Yueting Li; Siying Chen; Yonglin Wang; Aimin Wang; Yanyu Lan; Ting Liu; Lin Zheng
Journal:  Molecules       Date:  2019-10-27       Impact factor: 4.411

4.  The Effect of Inflammatory Priming on the Therapeutic Potential of Mesenchymal Stromal Cells for Spinal Cord Repair.

Authors:  Inés Maldonado-Lasunción; Agnes E Haggerty; Akinori Okuda; Tokumitsu Mihara; Natalia de la Oliva; Joost Verhaagen; Martin Oudega
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

5.  Multipotent mesenchymal stromal cells protect against kidney injury.

Authors:  Florian E Tögel; Joseph V Bonventre
Journal:  Cytotherapy       Date:  2013-06       Impact factor: 6.196

Review 6.  Immunobiology of mesenchymal stem cells.

Authors:  S Ma; N Xie; W Li; B Yuan; Y Shi; Y Wang
Journal:  Cell Death Differ       Date:  2013-11-01       Impact factor: 15.828

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.